@article{TGH3759,
author = {Seung-Hun Cho and Felix Berlth and Patrick Sven Plum and Till Herbold and Hakan Alakus and Robert Kleinert and Stefan Paul Moenig and Christiane Josephine Bruns and Arnulf Heinrich Hoelscher and Hans-Joachim Meyer},
title = {Gastric cancer treatment in the world: Germany},
journal = {Translational Gastroenterology and Hepatology},
volume = {2},
number = {5},
year = {2017},
keywords = {},
abstract = {Epidemiologically, around 15,500 persons per year contract gastric cancer with continuously decreasing incidence and a 5-year survival rate of only 30% to 35%. Contrary to the Asian countries, there are no prevention programs for gastric cancer in Germany, which leads to the disease frequently being diagnosed in locally advanced stages and predominantly being treated with multimodal therapy concepts. Complete (R0) resection is the therapy of choice for resectable gastric cancer. Special forms of gastric cancer that are limited to the mucosa can be endoscopically resected with a curative intent. Systematic D2 lymphadenectomy (LAD) plays a decisive role in the management of local advanced tumors because it significantly contributes to the reduction of tumor-related death and both local and regional relapse rates. Perioperative chemotherapy improves prognosis in the advanced stages, whereas palliative chemotherapy is normally indicated for metastatic diseases. Standardized resection procedures and the use of individualized multimodal therapy concepts have led to improvement in the 5-year survival rate.},
issn = {2415-1289}, url = {https://tgh.amegroups.org/article/view/3759}
}